Download by
Scanning QR Code
No Data
US Stock MarketDetailed Quotes
RAPT RAPT Therapeutics
Watchlist
15.110
-0.880-5.50% Close 10/03 16:00 ET
15.1100.0000.00%
Post 16:04 ET
15.790High14.960Low341.72KVolume
15.770Open15.990Pre Close5.18MTurnover1.19%Turnover RatioLossP/E (TTM)519.15MMarket Cap31.45052wk HighLossP/E (Static)34.36MShares14.96052wk Low2.60P/B434.11MFloat Cap51.210Historical High--Dividend TTM28.73MShs Float9.855Historical Low--Div YieldTTM5.19%Amplitude15.154Avg Price1Lot Size
Post-Market
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
About RAPT Therapeutics Company
Rapt Therapeutics, Inc. operates as a clinical stage immunology-based biopharmaceutical company, which engages in the discovery, development, and commercialization of oral small molecule therapies for patients in oncology and inflammatory diseases. The company was founded in 2015 and is headquartered in South San Francisco, CA.
News
Companies Like RAPT Therapeutics (NASDAQ:RAPT) Are In A Position To Invest In Growth
Benzinga's Top Ratings Upgrades, Downgrades For September 14, 2023
UpgradesAccording to OTR Global, the prior rating for Align Technology Inc (NASDAQ:ALGN) was changed from Mixed to Positive. For the second quarter, Align Tech had an EPS of $2.22, compared to year-ag
Berenberg Initiates Coverage On RAPT Therapeutics With Buy Rating, Announces Price Target of $34
Berenberg analyst Andy Chen initiates coverage on RAPT Therapeutics with a Buy rating and announces Price Target of $34.